Introduction
============

Gene expression studies are used as an independent predictive method for prognosis. In cancer genomic studies, tremendous effort has been devoted to pathway-based analysis. Pathway analysis is a promising tool to identify the mechanisms that underlie disease, adaptive physiological compensatory responses and new avenues for investigation. Different pathways have different biological functions. Thus, it is reasonable to study each pathway separately. Among the many pathways, only a few have predictive power for cancer development. Among genes within predictive pathways, there are subsets having small to moderate predictive power, whereas the remaining are noisy genes \[[@b1-can-5-189]--[@b6-can-5-189]\].

Background
==========

Genes have the inherent pathway structure, where pathways are composed of multiple genes with coordinated functions. The aim of this study was to identify genetic signatures associated with disease prognosis in bladder cancer with respect to hsa05219 pathway obtained from Kyoto Encyclopedia of Genes and Genomes (KEGG).

Methods
=======

Microarray data files were taken from Gene Expression Omnibus (GEO), accession number GSE7476. Four different types of data files were generated from GSE7476 experiment by analyzing gene expression profiles in normal bladder tissues (controls), low grade superficial tumour samples (pathologically classified as Ta low grade, named as Ta), high grade superficial tumours with an unclear clinical behaviour (T1 high grade, named as T1) and high grade muscle invasive tumours (pathologically classified as T2, T3 or T4, named as T2+).

Data files representing controls and high grade invasive tumours (T2+) were compared for the current review work.

Affymetrix data files
=====================

Affymetrix gene expression chip was used for their study and the intensity values seen in the data file were log transformed values. One would subtract the control value from the experimental value to find the significant change in expression level. 'Researchers generally' use a cut off at least 2-fold change (linear value) between control and experiment to 'screen significantly differentially expressed genes'.

Affymetrix does not have a certain threshold cut off that it recommends. Researchers in the community have seemed to adopt a value of about 100 (linear) so ∼6.65 (log). However, this does not mean that a value of 6.8 is expressed in a sample; this is just a general guideline that many researchers have adopted to filter out a bulk of the probe sets. Most researchers will first analyze the data based on fold change, then filter on intensity when a probe set is \<100 in both samples. A change from 3.5 to 4.8 in a sample could very well be just a background, where as a change from 6.0 to 7.4 might be real.

hsa05219 pathway
================

Pathway hsa05219 referring to bladder cancer was selected from KEGG pathway database (section 6.1 cancers <http://www.genome.jp/kegg/pathway.html>). There are totally 42 genes listed in hsa05219 pathway which are believed to be involved in causing bladder cancer ([Tables 1](#t1-can-5-189){ref-type="table"}--[](#t2-can-5-189){ref-type="table"}[3](#t3-can-5-189){ref-type="table"}).

Conclusion
==========

We have taken the list of genes associated with bladder cancer pathway from KEGG database. Log difference between the control and study subjects which exceeds more than 1.0 or less than −1.0 were first screened. *THBS1*, *RPS6KA5* and *CDKN1A* are the genes which are highly expressed in control when compared with study subjects (T2+). These genes are associated with 'angiogenesis', 'mitogen-activated protein kinase (MAPK) signaling pathway' and 'cell cycle', respectively. *ERBB2*, *TYMP*, *CDH1*, *TP53*, *DAPK1*, *CCND1*, *FGFR3*, *KRAS*, *E2F3*, *CDKN2A*, *VEGFA*, *MMP1* are the genes which are highly expressed in study when compared to control and these genes are associated with 'ErbB signaling pathway', 'nucleotide metabolism' 'adherens junction', 'p53 pathway', 'cell cycle', 'MAPK signaling pathway' and 'angiogenesis'. By this current pathway analysis approach to the GSE7476 bladder cancer datasets, we can say that genes like *ERBB2*, *TYMP*, *CDH1*, *TP53*, *DAPK1*, *CCND1*, *FGFR3*, *KRAS*, *E2F3*, *CDKN2A*, *VEGFA*, *MMP1* can be used as prognosis markers for bladder cancer gene expression study. Association of above 12 sets of genes for causing cancer was confirmed from Online Mendelian Inheritance in Man (OMIM) and articles from PubMed database. Further research is needed to evaluate whether the same gene signatures result from other bladder cancer profiling experiments ([Table 4](#t4-can-5-189){ref-type="table"}).

Difference in expression level
==============================

Significant findings
--------------------

According to KEGG pathway, '*hsa05219*' for bladder cancer, *RB*, *CDKN2A* and *p53* are considered as tumour suppressor genes and *FGFR3* and *HRAS* as oncogenes. Two of the tumour suppressor genes *CDKN2A* and *p53* were expressed in significant level when compared with normal tissue samples. *FGFR3* which is an oncogene is highly expressed in tumour samples compared to control tissue samples. *CDKN2A*, *p53* and *FGFR3* along with the other genes *ERBB2*, *TYMP*, *CDH1*, *DAPK1*, *CCND1*, *KRAS*, *E2F3*, *VEGFA* and *MMP1* are unregulated in tumour tissue samples. All these genes play an important role in ErbB signaling pathway, nucleotide metabolism, adherens junction, p53 pathway, MAPK signaling pathway, cell cycle and angiogenesis. *THBS1*, *RPS6KA5* and *CDKN1A* are downregulated in tumour tissue when compared with control tissue samples. Out of the 42 genes listed in the KEGG bladder cancer pathway, only eight genes *RASSF1*, *RB1*, *HRAS*, *EGFR*, *ERBB2*, *DAPK1*, *FGFR3* and *CDKN2A* have reference support to prove their involvement in causing bladder cancer. This current review suggest the lack of research/involvement of the other genes in the pathway to cause bladder cancer. Pathway analysis of affymetrix data file shows upregulation of four genes *ERBB2*, *DAPK1*, *FGFR3* and *CDKN2A* which have reference to prove their involvement in causing bladder cancer.

###### 

Gene list from hsa05219 pathway showing affymetrix ID, gene name, and gene ID

  **Sl no.**   **Affy ID**    **Gene name**   **Gene ID**
  ------------ -------------- --------------- -------------
  1            201109_s\_at   *THBS1*         7057
  2            204633_s\_at   *RPS6KA5*       9252
  3            202284_s\_at   *CDKN1A*        1026
  4            209946_at      *VEGFC*         7424
  5            202431_s\_at   *MYC*           4609
  6            204346_s\_at   *RASSF1*        11186
  7            203683_s\_at   *VEGFB*         7423
  8            224621_at      *MAPK1*         5594
  9            206742_at      *FIGF*          2277
  10           243829_at      *BRAF*          673
  11           212046_x\_at   *MAPK3*         5595
  12           206324_s\_at   *DAPK2*         23604
  13           215179_x\_at   *PGF*           5228
  14           1566678_at     *MMP2*          4313
  15           206254_at      *EGF*           1950
  16           203132_at      *RB1*           5925
  17           212983_at      *HRAS*          3265
  18           201895_at      *ARAF*          369
  19           202424_at      *MAP2K2*        5605
  20           203891_s\_at   *DAPK3*         1613
  21           211506_s\_at   *IL8*           3576
  22           201244_s\_at   *RAF1*          5894
  23           202670_at      *MAP2K1*        5604
  24           204947_at      *E2F1*          1869
  25           203936_s\_at   *MMP9*          4318
  26           211607_x\_at   *EGFR*          1956
  27           228361_at      *E2F2*          1870
  28           202246_s\_at   *CDK4*          1019
  29           202647_s\_at   *NRAS*          4893
  30           225160_x\_at   *MDM2*          4193
  31           216836_s\_at   *ERBB2*         2064
  32           204858_s\_at   *TYMP*          1890
  33           201131_s\_at   *CDH1*          999
  34           211300_s\_at   *TP53*          7157
  35           203139_at      *DAPK1*         1612
  36           208712_at      *CCND1*         595
  37           204379_s\_at   *FGFR3*         2261
  38           214352_s\_at   *KRAS*          3845
  39           203693_s\_at   *E2F3*          1871
  40           209644_x\_at   *CDKN2A*        1029
  41           211527_x\_at   *VEGFA*         7422
  42           204475_at      *MMP1*          4312

###### 

Displaying affymetrix grades and ID along with T2+ and control mean values

  **Sl no.**   **Affy grades**   **Affy ID**    **T2+ average**   **C average**   **Difference**
  ------------ ----------------- -------------- ----------------- --------------- ----------------
  1            A                 201109_s\_at   7.197941667       9.268797667     −2.070856
  2            A                 204633_s\_at   5.538698          6.974227667     −1.435529667
  3            A                 202284_s\_at   8.292146333       9.426557667     −1.134411333
  4            A                 209946_at      4.972374667       5.932246333     −0.959871667
  5            A                 202431_s\_at   9.570811333       10.20563933     −0.634828
  6            A                 204346_s\_at   5.68049           6.300829667     −0.620339667
  7            A                 203683_s\_at   4.670015333       5.256459        −0.586443667
  8            A                 224621_at      8.188972333       8.710883        −0.521910667
  9            A                 206742_at      3.331917667       3.622964        −0.291046333
  10           A                 243829_at      5.140807          5.374049333     −0.233242333
  11           A                 212046_x\_at   7.135151667       7.303775667     −0.168624
  12           A                 206324_s\_at   4.684244667       4.824944667     − 0.1407
  13           A                 215179_x\_at   7.105821667       7.123966        − 0.018144333
  14           A                 1566678_at     3.752619667       3.757442667     −0.004823
  15           A                 206254_at      3.159667333       3.112292333     0.047375
  16           A                 203132_at      6.140205333       6.082435667     0.057769667
  17           A                 212983_at      6.390220333       6.299536        0.090684333
  18           A                 201895_at      7.477000333       7.315159        0.161841333
  19           A                 202424_at      8.049549333       7.880261667     0.169287667
  20           A                 203891_s\_at   6.282708          6.019414667     0.263293333
  21           A                 211506_s\_at   7.225747667       6.952306667     0.273441
  22           A                 201244_s\_at   8.239435333       7.863649667     0.375785667
  23           A                 202670_at      7.602015          7.090296333     0.511718667
  24           A                 204947_at      5.903176333       5.286578333     0.616598
  25           A                 203936_s\_at   6.152433667       5.477768667     0.674665
  26           A                 211607_x\_at   5.508033333       4.786028667     0.722004667
  27           A                 228361_at      5.898566667       5.131460667     0.767106
  28           A                 202246_s\_at   8.944539333       8.051693        0.892846333
  29           A                 202647_s\_at   6.692538          5.796430333     0.896107667
  30           A                 225160_x\_at   7.044023333       6.121776667     0.922246667
  31           A                 216836_s\_at   9.437352333       8.389638667     1.047713667
  32           A                 204858_s\_at   6.671381333       5.556419        1.114962333
  33           A                 201131_s\_at   10.37200433       9.242416333     1.129588
  34           A                 211300_s\_at   5.945064333       4.792846667     1.152217667
  35           A                 203139_at      8.916442667       7.673051333     1.243391333
  36           A                 208712_at      8.620222333       7.024218667     1.596003667
  37           A                 204379_s\_at   9.858403          8.250372333     1.608030667
  38           A                 214352_s\_at   9.427273667       7.638116667     1.789157
  39           A                 203693_s\_at   7.203678333       5.31342         1.890258333
  40           A                 209644_x\_at   7.779116333       5.662257333     2.116859
  41           A                 211527_x\_at   8.164427333       6.013361333     2.151066
  42           A                 204475_at      8.622475667       4.105322667     4.517153

Log difference between the control and study subjects which exceeds more than 1.0 or less than −1.0 were first screened. Downregulated genes are marked in green and upregulated genes are marked in red with respect to tumour samples.

###### 

List displaying up and downregulated genes, downregulated genes are marked in green colour and up regulated genes are marked in red colour with respect to tumour samples

  **Sl No**   **Gene name**   **Difference**   **Pathways involved**
  ----------- --------------- ---------------- ---------------------------------
  1           *THBS1*         −2.07086         Angiogenesis
  2           *RPS6KA5*       −1.43553         MAPK signaling pathway
  3           *CDKN1A*        −1.13441         Cell cycle
  4           *ERBB2*         1.047714         ErbB signaling pathway
  5           *TYMP*          1.114962         Nucleotide metabolism
  6           *CDH1*          1.129588         Adherens junction
  7           *TP53*          1.152218         p53 pathway---tumour suppressor
  8           *DAPK1*         1.243391         MAPK signaling pathway
  9           *CCND1*         1.596004         Cell cycle
  10          *FGFR3*         1.608031         MAPK signaling pathway
  11          *KRAS*          1.789157         MAPK signaling pathway
  12          *E2F3*          1.890258         Cell cycle
  13          *CDKN2A*        2.116859         Cell cycle---tumour suppressor
  14          *VEGFA*         2.151066         Angiogenesis
  15          *MMP1*          4.517153         Angiogenesis

MAPK, mitogen-activated protein kinase.

###### 

Genes from the hsa05219 pathway involved in different cancers

  **Gene name**   **Diff (N-T2+)**   **From reference article**
  --------------- ------------------ --------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
  *THBS1*         −2.070856          Not related to any cancer
  *RPS6KA5*       −1.435529667       Not related to any cancer
  *CDKN1A*        −1.134411333       Cervical cancer
  *VEGFC*         −0.959871667       Gastric cancer
  *MYC*           −0.634828          Acute lymphoblastic leukaemia (ALL) (precursor B lymphoblastic leukaemia), ALL (precursor T lymphoblastic leukaemia), Burkitt lymphoma, multiple myeloma, small cell lung cancer, oral cancer, penile cancer, ovarian cancer, choriocarcinoma, breast cancer, osteosarcoma, Kaposi's sarcoma, laryngeal cancer
  *RASSF1*        −0.620339667       Non-small cell lung cancer, bladder cancer, nasopharyngeal cancer
  *VEGFB*         −0.586443667       Gastric cancer
  *MAPK1*         −0.521910667       Not related to any cancer
  *FIGF*          −0.291046333       Gastric cancer
  *BRAF*          −0.233242333       Thyroid and malignant cancer
  *MAPK3*         −0.168624          Not related to any cancer
  *DAPK2*         −0.1407            Not related to any cancer
  *PGF*           −0.018144333       Not related to any cancer
  *MMP2*          −0.004823          Choriocarcinoma
  *EGF*           0.047375           Gastric cancer
  *RB1*           0.057769667        Chronic myeloid leukaemia (CML), small cell lung cancer, oesophageal cancer, breast cancer, osteosarcoma, glioma, hepatocellular carcinoma
  *HRAS*          0.090684333        Bladder, penile, cervical, thyroid cancer, squamous cell carcinoma, hepatocellular carcinoma
  *ARAF*          0.161841333        Not related to any cancer
  *MAP2K2*        0.169287667        Not related to any cancer
  *DAPK3*         0.263293333        Not related to any cancer
  *IL8*           0.273441           Not related to any cancer
  *RAF1*          0.375785667        Not related to any cancer
  *MAP2K1*        0.511718667        Not related to any cancer
  *E2F1*          0.616598           Not related to any cancer
  *MMP9*          0.674665           Penile cancer
  *EGFR*          0.722004667        Oral cancer, oesophageal, gastric, bladder, cervical, laryngeal cancer, glioma and choriocarcinoma
  *E2F2*          0.767106           Not related to any cancer
  *CDK4*          0.892846333        Cervical cancer, malignant melanoma, glioma
  *NRAS*          0.896107667        Acute myeloid leukaemia (AML), multiple myeloma, oral cancer, thyroid cancer, adrenal carcinoma, malignant melanoma, hepatocellular carcinoma, autoimmune lymphoproliferative syndromes
  *MDM2*          0.922246667        Penile cancer, choriocarcinoma, osteosarcoma, alveolar rhabdmycosarcoma and glioma
  *ERBB2*         1.047713667        Gastric, pancreatic, bladder, endometrial, ovarian, cervical, breast cancer, choriocarcinoma, cholangiocarcinoma
  *TYMP*          1.114962333        Not related to any cancer
  *CDH1*          1.129588           Gastric, penile, breast, thyroid, nasopharyngeal cancer and hepatocellular carcinoma
  *TP53*          1.152217667        MAPK signaling pathway, cell cycle, p53 signaling pathway, apoptosis, Wnt signaling pathway, neurotrophin signaling pathway, amyotrophic lateral sclerosis, Huntington's disease, pathways in cancer, colorectal cancer, pancreatic cancer, endometrial cancer, glioma, prostate cancer, thyroid cancer, basal cell carcinoma, melanoma, bladder cancer, CML, small cell lung cancer, non-small cell lung cancer
  *DAPK1*         1.243391333        Bladder cancer
  *CCND1*         1.596003667        Hairy-cell leukemia, multiple myeloma, oral cancer, oesophageal cancer, breast cancer, laryngeal cancer
  *FGFR3*         1.608030667        Multiple myeloma and bladder cancer
  *KRAS*          1.789157           AML, multiple myeloma, non-small cell lung cancer, oral cancer, gastric cancer, pancreatic cancer, colorectal cancer, endometrial cancer, ovarian cancer, cervical cancer, thyroid cancer, squamous cell carcinoma, Kaposi's sarcoma, cholangiocarcinoma, gallbladder cancer, hepatocellular carcinoma
  *E2F3*          1.890258333        Not related to any cancer
  *CDKN2A*        2.116859           CML, Burkitt lymphoma, adult T-cell leukemia, non-small cell lung cancer, malignant pleural mesothelioma, oral cancer, oesophageal cancer, pancreatic cancer, bladder cancer, penile cancer, osteosarcoma, malignant melanoma, squamous cell carcinoma, glioma, malignant islet cell carcinoma, cholangiocarcinoma, gallbladder cancer, hepatocellular carcinoma, nasopharyngeal cancer, laryngeal cancer, type II diabetes mellitus
  *VEGFA*         2.151066           Gastric cancer
  *MMP1*          4.517153           Choriocarcinoma

Log difference between the control and study subjects which exceeds more than 1.0 or less than −1.0 were first screened. Downregulated genes are marked in green and upregulated genes are marked in red with respect to tumour samples.
